Literature DB >> 16510558

Potentiation of native and recombinant P2X7-mediated calcium signaling by arachidonic acid in cultured cortical astrocytes and human embryonic kidney 293 cells.

Susanna Alloisio1, Rita Aiello, Stefano Ferroni, Mario Nobile.   

Abstract

In the brain, arachidonic acid (AA) plays a critical role in the modulation of a broad spectrum of biological responses, including those underlying neuroinflammation. By using microfluorometry, we investigated the action of extracellular AA in the modulation of the purinoceptor P2X7-mediated elevation of [Ca(2+)](i) in cultured neocortical type-1 astrocytes and P2X7-, P2X2-transfected human embryonic kidney (HEK) 293 cells. We report that in cultured astrocytes, AA-induced [Ca(2+)](i) elevation is coupled to depletion of intracellular Ca(2+) stores and to a sustained noncapacitative Ca(2+) entry. AA also induced a robust potentiation of the astrocytic P2X7-mediated [Ca(2+)](i) rise evoked by the selective agonist 3'-O-(4-benzoyl)benzoyl-ATP (BzATP). Pharmacological studies demonstrate that the selective P2X7 antagonists oxidized ATP and Brilliant Blue G abrogated the AA-mediated potentiation of BzATP-evoked [Ca(2+)](i) elevation. Fluorescent dye uptake experiments showed that the AA-induced increase in [Ca(2+)](i) was not due to a switch of the P2X7 receptor from channel to the pore mode of gating. The synergistic effect of AA and BzATP was also observed in HEK293 cells stably expressing rat and human P2X7 but not in rat P2X2. Control HEK293 cells responded to AA exposure only with a transient [Ca(2+)](i) elevation, whereas in those expressing the P2X7 receptor, AA elicited a potentiation of the BzATP-induced [Ca(2+)](i) rise. Together, these findings indicate that AA mediates a complex regulation of [Ca(2+)](i) dynamics also through P2X7-mediated Ca(2+) entry, suggesting that variations in AA production may be relevant to the control of both the temporal and spatial kinetics of [Ca(2+)](i) signaling in astroglial cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16510558     DOI: 10.1124/mol.105.020164

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  8 in total

1.  Negative and positive allosteric modulators of the P2X(7) receptor.

Authors:  A D Michel; L J Chambers; D S Walter
Journal:  Br J Pharmacol       Date:  2007-12-10       Impact factor: 8.739

Review 2.  Arachidonic acid and ion channels: an update.

Authors:  H Meves
Journal:  Br J Pharmacol       Date:  2008-06-16       Impact factor: 8.739

3.  Positive allosteric modulation by ivermectin of human but not murine P2X7 receptors.

Authors:  W Nörenberg; H Sobottka; C Hempel; T Plötz; W Fischer; G Schmalzing; M Schaefer
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

4.  Clemastine potentiates the human P2X7 receptor by sensitizing it to lower ATP concentrations.

Authors:  Wolfgang Nörenberg; Christoph Hempel; Nicole Urban; Helga Sobottka; Peter Illes; Michael Schaefer
Journal:  J Biol Chem       Date:  2011-01-24       Impact factor: 5.157

5.  Agonists, Antagonists, and Modulators of P2X7 Receptors.

Authors:  Christa E Müller; Vigneshwaran Namasivayam
Journal:  Methods Mol Biol       Date:  2022

6.  The human cathelicidin LL-37 modulates the activities of the P2X7 receptor in a structure-dependent manner.

Authors:  Linda Tomasinsig; Cinzia Pizzirani; Barbara Skerlavaj; Patrizia Pellegatti; Sara Gulinelli; Alessandro Tossi; Francesco Di Virgilio; Margherita Zanetti
Journal:  J Biol Chem       Date:  2008-09-02       Impact factor: 5.157

7.  Up-regulation of cPLA(2) gene expression in astrocytes by all three conventional anti-bipolar drugs is drug-specific and enzyme-specific.

Authors:  Baoman Li; Li Gu; Hongyan Zhang; Jingyang Huang; Ye Chen; Leif Hertz; Liang Peng
Journal:  Psychopharmacology (Berl)       Date:  2007-06-27       Impact factor: 4.530

8.  Agonist potency at P2X7 receptors is modulated by structurally diverse lipids.

Authors:  A D Michel; E Fonfria
Journal:  Br J Pharmacol       Date:  2007-08-13       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.